Abstract
Our study demonstrates that tamoxifen, when administered to postmenopausal women at a conventional dosage, reduces LDL levels and protects LDL from oxidation. The protective effect of tamoxifen against the development of breast cancer in women considered at risk is being investigated in a placebo-controlled trial sponsored by the National Institutes of Health. Whether tamoxifen also protects against the development of cardiovascular disease in this trial is also of considerable interest.
Original language | English |
---|---|
Pages (from-to) | 1072-1073 |
Number of pages | 2 |
Journal | The American Journal of Cardiology |
Volume | 76 |
Issue number | 14 |
DOIs | |
State | Published - 15 Nov 1995 |
Externally published | Yes |